{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:21Z","timestamp":1792839861894,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40263-022-00949-7","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:05:22Z","timestamp":1662548722000},"page":"1133-1141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1007","volume":"36","author":[{"given":"Tina","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"12","key":"949_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders\u2014from mechanisms to trials. Nat Rev Neurol. 2021;17(12):759\u201373.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"949_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177.","journal-title":"Neurology"},{"issue":"5","key":"949_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001034","volume":"8","author":"J Li","year":"2021","unstructured":"Li J, Bazzi SA, Schmitz F, et al. Molecular level characterization of circulating aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8(5): e1034.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"949_CR4","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","volume":"11","author":"AM Agasing","year":"2020","unstructured":"Agasing AM, Wu Q, Khatri B, et al. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun. 2020;11(1):2856.","journal-title":"Nat Commun"},{"issue":"1","key":"949_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1\u201316.","journal-title":"J Neurol"},{"issue":"2","key":"949_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000947","volume":"8","author":"SH Kim","year":"2021","unstructured":"Kim SH, Jang H, Park NY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm. 2021;8(2): e947.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"949_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60\u20137.","journal-title":"Lancet Neurol"},{"key":"949_CR8","unstructured":"Horizon Therapeutics USA Inc. UPLIZNA (inebilizumab-cdon) injection, for intravenous use [US prescribing information]. 2021. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 17 Aug 2022."},{"key":"949_CR9","unstructured":"Viela Bio B.V. Uplizna : EPAR - product information. 2022. https:\/\/www.ema.europa.eu\/. Accessed 17 Aug 2022."},{"key":"949_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm5120107","volume":"5","author":"D Chen","year":"2016","unstructured":"Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5:12.","journal-title":"J Clin Med"},{"issue":"2","key":"949_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580\u20136.","journal-title":"J Immunol"},{"issue":"2","key":"949_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1352458517740641","volume":"25","author":"MA Agius","year":"2019","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2019;25(2):235\u201345.","journal-title":"Mult Scler"},{"issue":"131","key":"949_CR13","first-page":"1","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(131):1\u201314.","journal-title":"Arthritis Res Ther"},{"issue":"10206","key":"949_CR14","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"6","key":"949_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/13524585211047223","volume":"28","author":"M Rensel","year":"2021","unstructured":"Rensel M, Zabeti A, Mealy MA, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial. Mult Scler. 2021;28(6):925\u201332.","journal-title":"Mult Scler"},{"issue":"Suppl 2","key":"949_CR16","first-page":"151","volume":"27","author":"JL Bennett","year":"2021","unstructured":"Bennett JL, Aktas O, Smith M, et al. Extent of B-cell depletion is associated with disease activity reduction in neuromyelitis optica spectrum disorder: results from the N-MOmentum study [abstract no. P028]. Mult Scler. 2021;27(Suppl 2):151\u20132.","journal-title":"Mult Scler"},{"key":"949_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40262-021-01071-5","volume":"61","author":"L Yan","year":"2021","unstructured":"Yan L, Kimko H, Wang B, et al. Population pharmacokinetic modeling of inebilizumab in subjects with neuromyelitis optica spectrum disorders, systemic sclerosis, or relapsing multiple sclerosis. Clin Pharmacokinet. 2021;61:387\u2013400.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"949_CR18","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"7","key":"949_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458515620934","volume":"22","author":"BAC Cree","year":"2016","unstructured":"Cree BAC, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica\u2014ethical and design considerations. Mult Scler. 2016;22(7):862\u201372.","journal-title":"Mult Scler"},{"issue":"3","key":"949_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/2168479015619203","volume":"50","author":"K Patra","year":"2016","unstructured":"Patra K, Cree BAC, Katz E, et al. Statistical considerations for an adaptive design for a serious rare disease. Ther Innov Regul Sci. 2016;50(3):375\u201384.","journal-title":"Ther Innov Regul Sci."},{"issue":"13","key":"949_CR21","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1177\/1352458521988926","volume":"27","author":"BAC Cree","year":"2021","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021;27(13):2052\u201361.","journal-title":"Mult Scler"},{"issue":"103352","key":"949_CR22","first-page":"1","volume":"57","author":"EP Flanagan","year":"2022","unstructured":"Flanagan EP, Levy M, Katz E, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum study. Mult Scler Relat Disord. 2022;57(103352):1\u20136.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"949_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000978","volume":"8","author":"R Marignier","year":"2021","unstructured":"Marignier R, Bennett JL, Kim HJ, et al. Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):1\u201315.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"949_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, Smith MA, Rees WA, et al. Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol. 2021;89(5):895\u2013910.","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"949_CR25","first-page":"158","volume":"27","author":"BAC Cree","year":"2021","unstructured":"Cree BAC, Bennett JL, Weinshenker BG, et al. Safety and efficacy of inebilizumab in NMOSD over a mean treatment duration of 3.2 years: end of study data from the N-MOmentum trial [abstract no. P037]. Mult Scler. 2021;27(Suppl 2):158\u201360.","journal-title":"Mult Scler"},{"key":"949_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103356","volume":"57","author":"R Marignier","year":"2022","unstructured":"Marignier R, Pittock SJ, Paul F, et al. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022;57:103356.","journal-title":"Mult Scler Relat Disord."},{"key":"949_CR27","unstructured":"Bernitsas E, Cimbora D, Dinh Q, et al. Safety, efficacy and pharmacokinetics of inebilizumab in African Americans with neuromyelitis optica spectrum disorder [abstract no P284 and Poster]. In: Americas Committee for Treatment and Research in Multiple Sclerosis 2022 Forum. 2022."},{"issue":"3","key":"949_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000977","volume":"8","author":"A Avouac","year":"2021","unstructured":"Avouac A, Maarouf A, Stellmann JP, et al. Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e977.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"949_CR29","unstructured":"Alexion Pharmaceuticals Inc. SOLIRIS (eculizumab) injection, for intravenous use [US prescribing information]. 2022. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 17 Aug 2022."},{"key":"949_CR30","unstructured":"Alexion Europe SAS. Soliris : EPAR\u2014product information. 2021. https:\/\/www.ema.europa.eu\/. Accessed 17 Aug 2022."},{"key":"949_CR31","unstructured":"Genentech Inc. ENSPRYNG (satralizumab-mwge) injection, for subcutaneous use [US prescribing information]. 2020. https:\/\/dailymed.nlm.nih.gov\/dailymed\/. Accessed 17 Aug 2022."},{"key":"949_CR32","unstructured":"Roche Registration GmbH. Enspryng: EPAR\u2014product information. 2021. https:\/\/www.ema.europa.eu\/. Accessed 17 Aug 2022."},{"issue":"1","key":"949_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","volume":"11","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Zhang I, Kielhorn A, et al. Network meta-analysis of Food and Drug Administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Neurol Ther. 2022;11(1):123\u201335.","journal-title":"Neurol Ther."},{"key":"949_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00376-2","author":"BAC Cree","year":"2022","unstructured":"Cree BAC, Greenberg B, Cameron C, et al. Letter to the editor regarding \u201cNetwork meta-analysis of Food and Drug Administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.\u201d Neurol Ther. 2022. https:\/\/doi.org\/10.1007\/s40120-022-00376-2.","journal-title":"Neurol Ther."},{"key":"949_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00378-0","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Zhang I, Kielhorn A, et al. A response to: Letter to the editor regarding \u201cNetwork meta-analysis of Food and Drug Administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.\u201d Neurol Ther. 2022. https:\/\/doi.org\/10.1007\/s40120-022-00378-0.","journal-title":"Neurol Ther."},{"issue":"7","key":"949_CR36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"5","key":"949_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"key":"949_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fneur.2020.00778","volume":"11","author":"S Asseyer","year":"2020","unstructured":"Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies. Front Neurol. 2020;11:778.","journal-title":"Front Neurol"},{"issue":"3","key":"949_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000985","volume":"8","author":"I Ayzenberg","year":"2021","unstructured":"Ayzenberg I, Richter D, Henke E, et al. Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e985.","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"updated-by":[{"DOI":"10.1007\/s40263-022-00957-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00949-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00949-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T13:16:44Z","timestamp":1665407804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00949-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00949-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"17 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-022-00957-7","URL":"https:\/\/doi.org\/10.1007\/s40263-022-00957-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tina Nie and Hannah Blair are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}